Regenesis

Kimera® Labs Inc publishes novel brain targeting of exosomes in Nature Scientific Reports

Retrieved on: 
Tuesday, February 20, 2024

The article, "Use of transcranial low-intensity focused ultrasound for targeted delivery of stem cell-derived exosomes to the brain" was published on October 18, 2023 in Nature Scientific Reports.

Key Points: 
  • The article, "Use of transcranial low-intensity focused ultrasound for targeted delivery of stem cell-derived exosomes to the brain" was published on October 18, 2023 in Nature Scientific Reports.
  • The study findings published in Nature Scientific Reports concluded that a statistically significant amount of Kimera®'s exosomes penetrated the BBB by employing focused ultrasound on a targeted region of the rat brain.
  • Kimera®'s neural study employing exosomes combined with focused ultrasound is considered a material advancement by the scientific community in the challenging targeted brain delivery field.
  • The Company is in the process of advancing further neural scientific and clinical developments with its exosomes employing focused ultrasound.

Kimera® Labs Inc publishes novel brain targeting of exosomes in Nature Scientific Reports

Retrieved on: 
Tuesday, February 20, 2024

The article, "Use of transcranial low-intensity focused ultrasound for targeted delivery of stem cell-derived exosomes to the brain" was published on October 18, 2023 in Nature Scientific Reports.

Key Points: 
  • The article, "Use of transcranial low-intensity focused ultrasound for targeted delivery of stem cell-derived exosomes to the brain" was published on October 18, 2023 in Nature Scientific Reports.
  • The study findings published in Nature Scientific Reports concluded that a statistically significant amount of Kimera®'s exosomes penetrated the BBB by employing focused ultrasound on a targeted region of the rat brain.
  • Kimera®'s neural study employing exosomes combined with focused ultrasound is considered a material advancement by the scientific community in the challenging targeted brain delivery field.
  • The Company is in the process of advancing further neural scientific and clinical developments with its exosomes employing focused ultrasound.

Regenesis Achieves FDA Clearance for the New Reprieve by Regenesis™ Device

Retrieved on: 
Tuesday, August 22, 2023

SCOTTSDALE, Ariz., Aug. 22, 2023 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical devic­­e company focused on safe, non-drug, pain management, announced today commercialization of the new Reprieve by Regenesis™ device (Reprieve). Reprieve is the only home-use shortwave diathermy device on the market and is based on Regenesis' core pulsed electromagnetic energy platform.

Key Points: 
  • SCOTTSDALE, Ariz., Aug. 22, 2023 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical devic­­e company focused on safe, non-drug, pain management, announced today commercialization of the new Reprieve by Regenesis™ device (Reprieve).
  • Reprieve is the only home-use shortwave diathermy device on the market and is based on Regenesis' core pulsed electromagnetic energy platform.
  • "In alignment with our Vision to improve health for a longer, more active, and fulfilling life, we are pleased to announce we received Food and Drug Administration (FDA) clearance for our new Reprieve by Regenesis device," said Tom Eisiminger, President and CEO.
  • Because our new device has a two-treatment applicator option, we are expanding our efforts into the podiatric space with a focus on the treatment of pain associated with diabetic neuropathy."

BioVie Issues Letter to Shareholders

Retrieved on: 
Tuesday, October 4, 2022

Thus, Ive prepared this shareholders letter to explain our excitement and to provide updates on our other programs.

Key Points: 
  • Thus, Ive prepared this shareholders letter to explain our excitement and to provide updates on our other programs.
  • BioVie has always held and the data from thousands of publications suggest that Alzheimers disease pathology is driven by multiple factors.
  • BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative therapies to overcome unmet medical needs in chronic debilitating conditions.
  • Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained.

Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory Board

Retrieved on: 
Tuesday, July 26, 2022

SAN DIEGO, July 26, 2022 /PRNewswire/ --Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of geneticist George M. Church, Ph.D., who will serve as Chair of Poseida's newly formed Gene Therapy Scientific Advisory Board (SAB).

Key Points: 
  • SAN DIEGO, July 26, 2022 /PRNewswire/ --Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of geneticist George M. Church, Ph.D., who will serve as Chair of Poseida's newly formed Gene Therapy Scientific Advisory Board (SAB).
  • "We are honored to have Dr. Church, a pioneer in the fields of genome engineering, systems biology and synthetic biology, join Poseida's Scientific Advisory Board.
  • "Dr. Church's depth of knowledge and experience, both in academia and industry, will make him a tremendous asset as Chair of our newly created Gene Therapy Scientific Advisory Board and we look forward to working with him as we build out this group of advisors."
  • "As we develop in vivo gene therapies for rare diseases in patient populations with high unmet medical need, I am thrilled to have Dr. Church lead our Gene Therapy SAB," said Brent Warner, President, Gene Therapy at Poseida.

Eclipse Regenesis Awarded National Institutes of Health (NIH) Grant

Retrieved on: 
Thursday, August 26, 2021

Eclipse Regenesis , Inc., developer of the first restorative therapy to address pediatric and adult Short Bowel Syndrome, has been awarded a National Institutes of Health Small Business Innovation Research (NIH SBIR) Fast Track grant of $1.7 million.

Key Points: 
  • Eclipse Regenesis , Inc., developer of the first restorative therapy to address pediatric and adult Short Bowel Syndrome, has been awarded a National Institutes of Health Small Business Innovation Research (NIH SBIR) Fast Track grant of $1.7 million.
  • We are honored that the National Institutes of Health (NIH) has funded our SBIR proposal as there is a huge unmet clinical need in a rare, but very debilitating, condition that we are trying to address, said Eclipse Regenesis CEO Andre Bessette.
  • This funding for Eclipse Regenesis, Inc. is supported by The National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under award number R44DK127658.
  • The company also recently received a National Science Foundation Small Business Innovation Research grant to support development of a minimally-invasive version of the Eclipse XL1 System.